Clinical study on Pingfeng Shengmai Capsules combined with Salmeterol Xinafoate and Fluticasone Propionate Aerosol in treatment of bronchial asthma
Zhen-ming LIANG,Guang-sheng WU,Yan-tong FANG,Yin-yan ZHU,Ya-fei ZHU
DOI: https://doi.org/10.7501/j.issn.1674-5515.2017.01.014
2017-01-01
Abstract:Objective To investigate the clinical efficacy of Pingfeng Shengmai Capsules combined with Salmeterol Xinafoate and Fluticasone Propionate Aerosol in treatment of bronchial asthma. Methods Patients (84 cases) with bronchial asthma in Hangzhou Normal University Affiliated Hospital from September 2015 to September 2016 were divided into control group (42 cases) and treatment group (42 cases) based on different treatments. Patients in the control group were inhalation administered with Salmeterol Xinafoate and Fluticasone Propionate Aerosol, 1 suck/time, twice daily. Patients in the treatment group were po administered with Pingfeng Shengmai Capsules on the basis of the control group, 3 grain/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and clinical symptoms disappeared time, pulmonary function indexes FEV1, FVC, and PEF and serological indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.95%and 95.24%, respectively, and there were differences between two groups (P<0.05). After treatment, clinical symptoms disappeared time of wheezing, cough, and lung rale in two groups was decreased with significant difference between two groups (P<0.05). FEV1, FVC, and PEF levels in two groups were increased, and there were significant differences between two groups before and after treatment (P<0.05). And the increase degree of FEV1, FVC, and PEF levels in the treatment group was more significant than that in the control group (P<0.05). The levels of IL-4, IL-6, TNF-α, and NO in two groups were lower than those before treatment, while the levels of IL-10 and SOD were higher than those before treatment (P<0.05). And the improve degree of those indexes in the treatment group was more significant than that in the control group (P<0.05). Conclusion Pingfeng Shengmai Capsules combined with Salmeterol Xinafoate and Fluticasone Propionate Aerosol has a significant clinical effect in treatment of bronchial asthma, can improve clinical symptoms and pulmonary function, and decrease system inflammatory response, which has a certain clinical application value.